RhumbLine Advisers
IKT icon

RhumbLine Advisers’s Inhibikase Therapeutics IKT Stock Holding History

RhumbLine Advisers’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$98.6K Buy
58,717
+11,554
+24% +$20.5K ﹤0.01% 3414
2025
Q4 		$96.7K Sell
47,163
-10,388
-18% -$16.5K ﹤0.01% 3485
2025
Q3 		$93.2K Sell
57,551
-973
-2% -$1.69K ﹤0.01% 3542
2025
Q2 		$114K Buy
+58,524
New +$115K ﹤0.01% 3489

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RhumbLine Advisers's IKT Position: Q1 2026 in Review

RhumbLine Advisers increased its Inhibikase Therapeutics (IKT) stake by 24% in Q1 2026, buying an estimated $20.5K and bringing the position to 58,717 shares worth $98.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3414.

RhumbLine Advisers first reported a position in IKT in Q2 2025 and has held it in 4 quarters since. The position peaked at $114K in Q2 2025. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • RhumbLine Advisers held 58,717 shares of Inhibikase Therapeutics worth $98.6K as of Q1 2026.
  • RhumbLine Advisers bought 11,554 Inhibikase Therapeutics shares in Q1 2026, an estimated $20.5K.
  • Inhibikase Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3414 holding.
  • RhumbLine Advisers first reported a position in Inhibikase Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • RhumbLine Advisers's Inhibikase Therapeutics position peaked at $114K in Q2 2025.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.